Echinocandins Versus Azoles for Candidemia Treatment

NCT03799172 | Completed

• 1 other identifier: CRC_GHN_2019_001
• Study Type: observational
• Target: 79
• Locations: 1 country
• Sites: 1

Brief Summary

Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. Successful clinical outcome requires early diagnosis and effective antifungal therapy. Guidelines for the treatment of candidemia were published by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). According to these guidelines, echinocandins are the preferred first-line therapy for candidemia in critically ill patients. Considering the bibliography supporting this statement, the place of triazoles still needs to be defined in candidemia therapeutic arsenal. In this context, we are setting up a retrospective cohort study using Hospital database to compare the efficacy of echinocandins and azoles for the treatment of candidemia in intensive care units.

Conditions

Candidemia

Outcome Measures

Primary Outcomes (1)

• Comparison of all cause hospital mortality on day 90 between echinocandins and azoles

  Comparison of all cause hospital mortality on day 90 between echinocandins and azoles

  Mortality on day 90 after antifungal initiation

Secondary Outcomes (1)

• Comparison of treatment success on day 30 between echinocandins and azoles.

  Treatment success on day 30 after antifungal initiation

Study Arms (2)

Echinocandin group

Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia

Drug: Echinocandin treatment

Triazole group

Triazole group is the group of patients who received triazoles as first-line therapy for candidemia

Drug: Triazole treatment

Interventions

Echinocandin treatment DRUG

Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care

Echinocandin group

Triazole treatment DRUG

Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care. Candidemia was defined as at least one blood culture positive for Candida.

Triazole group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with a diagnosis of candidemia during their ICU stay

You may qualify if:

• Patients who had a diagnosis of candidemia during ICU stay and were treated with echinocandins or azoles

You may not qualify if:

• Patients with neutropenia
• Patients without antifungal treatment
• Patients who received antifungal therapy for more than two days before candidemia diagnosis
• Patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy
• Patients who received less than 4 days of antifungal therapy after candidemia diagnosis

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Hospices Civils de Lyon, Hôpital de la Croix-Rousse

Lyon, 69004, France

Location

MeSH Terms

Conditions

Candidemia

Condition Hierarchy (Ancestors)

Candidiasis, Invasive; Candidiasis; Mycoses; Bacterial Infections and Mycoses; Infections; Invasive Fungal Infections; Fungemia; Sepsis; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 3, 2019
• First Posted: January 10, 2019
• Study Start: November 1, 2018
• Primary Completion: February 1, 2019
• Study Completion: September 1, 2019
• Last Updated: March 4, 2020

Record last verified: 2020-03

Locations

FR (1)